← All Settlements
Health & Safety 285 days left to file

Zantac (Ranitidine) Cancer Settlement

vs. Sanofi, GSK, Boehringer Ingelheim, Pfizer

Manufacturers of Zantac heartburn medication face claims that the drug contained NDMA, a probable human carcinogen, and failed to warn consumers about cancer risks.

Filing Deadline
December 31, 2026
285 days remaining
Estimated Payout
$500 — $3,000,000
TBD (Est. $10B+) total fund
Proof Required
Yes

Who's Eligible?

Individuals who regularly took Zantac (ranitidine) and were later diagnosed with cancer, particularly bladder, stomach, liver, esophageal, or pancreatic cancer.

  • Must have used Zantac/ranitidine regularly (at least once per week for a year or more)
  • Must have been diagnosed with a qualifying cancer after using the product
  • Qualifying cancers include: bladder, stomach, liver, esophageal, pancreatic, colorectal
  • No age restriction on claims

Proof Requirements

Required documentation:

  • Medical records confirming cancer diagnosis
  • Evidence of Zantac/ranitidine use (pharmacy records, declarations)
  • Treatment records

Settlement Details

Zantac (ranitidine), one of the world's best-selling heartburn medications, was pulled from the market in 2020 after testing revealed it contained unacceptable levels of N-Nitrosodimethylamine (NDMA), a probable carcinogen. Users who developed certain cancers after taking Zantac may be eligible for compensation.

Individual settlement negotiations are ongoing with payouts expected to vary significantly based on cancer type, duration of use, and other factors.

Case Information

Case Number9:20-md-02924-RLR
CourtU.S. District Court, Southern District of Florida
Settlement AdministratorMDL Settlement Administrator
Statusopen

Ready to File Your Claim?

You have 285 days left. Don't leave money on the table.

File Directly (Free) → Get Filing Assistance ($5-15)